Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2023

15-05-2023 | Stem Cell Transplantion | Letter to the Editor

Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient

Authors: Julia Bini Viotti, Fabian Dammann, Antonio Martin Jimenez Jimenez, Anthony D. Anderson, Michele I. Morris, Jose F. Camargo, Mohammed Raja

Published in: Annals of Hematology | Issue 8/2023

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Papanicolaou GA, Silveira FP, Langston AA et al (2019) Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis 68:1255–1264CrossRefPubMed
2.
Maertens J, Cordonnier C, Jaksch P et al (2019) Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med 381:1136–1147CrossRefPubMed
3.
Avery RK, Alain S, Alexander BD et al (2022) Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis 75:690–701CrossRefPubMed
4.
Chemaly RF, Ullmann AJ, Stoelben S et al (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370:1781–1789CrossRefPubMed
5.
Marty FM, Ljungman P, Chemaly RF et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433–2444CrossRefPubMed
6.
Marty FM, Ljungman PT, Chemaly RF et al (2020) Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant 20:1703–1711CrossRefPubMed
7.
Ljungman P, Schmitt M, Marty FM et al (2020) A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis 70:1525–1533CrossRefPubMed
8.
Chou S, Wu J, Song K et al (2019) Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral Res 172:104616CrossRefPubMedPubMedCentral
9.
Chou S, Song K, Wu J, Bo T, Crumpacker C (2022) Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. J Infect Dis 226(4):576–584CrossRefPubMed
10.
Schubert A, Ehlert K, Schuler-Luettmann S, Gentner E, Mertens T, Michel D (2013) Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis 13:330CrossRefPubMedPubMedCentral
Metadata
Title
Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient
Authors
Julia Bini Viotti
Fabian Dammann
Antonio Martin Jimenez Jimenez
Anthony D. Anderson
Michele I. Morris
Jose F. Camargo
Mohammed Raja
Publication date
15-05-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05265-8

Other articles of this Issue 8/2023

Annals of Hematology 8/2023 Go to the issue

Original Article

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

Letter to the Editor

Establishment of the Abu Dhabi Emirate Thalassemia Longitudinal Cohort (AD-TLC): leveraging the power of observation

Letter to the Editor

Response to: meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data

Letter to the Editor

Acute liver failure associated with human adenovirus infection after allogeneic hematopoietic stem cell transplantation

Original Article

N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study

Original Article

Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits